SNT-3012

SNT-3012 is a preclinical therapeutic candidate developed by Sonata Therapeutics, classified as a "Network Medicine." It is being investigated for the treatment of pancreatic and colorectal cancers, both of which are characterized by complex disease networks and limited effective therapies. Network Medicines are designed to reprogram diseased cells so they release specific therapeutic signals that coordinate all key cell types within the disease network, aiming to drive immune-mediated tumor rejection and overall disease resolution. Preclinical studies with SNT-3012 have demonstrated significant tumor regression in both immunologically "hot" (warm) and "cold" syngeneic tumor models. The drug leverages modulation of the tumor microenvironment as its primary mechanism[1][6][7].